Immuron Ltd - Asset Resilience Ratio
Immuron Ltd (IMC) has an Asset Resilience Ratio of 29.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Immuron Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Immuron Ltd's Asset Resilience Ratio has changed over time. See Immuron Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Immuron Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Immuron Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$3.04 Million | 29.97% |
| Total Liquid Assets | AU$3.04 Million | 29.97% |
Asset Resilience Insights
- Very High Liquidity: Immuron Ltd maintains exceptional liquid asset reserves at 29.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Immuron Ltd Industry Peers by Asset Resilience Ratio
Compare Immuron Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Immuron Ltd (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Immuron Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 29.97% | AU$3.04 Million ≈ $2.15 Million |
AU$10.13 Million ≈ $7.17 Million |
-- |
| 2024-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$15.55 Million ≈ $11.00 Million |
-- |
| 2023-06-30 | 8.34% | AU$1.83 Million ≈ $1.30 Million |
AU$21.99 Million ≈ $15.56 Million |
+0.96pp |
| 2022-06-30 | 7.38% | AU$1.83 Million ≈ $1.30 Million |
AU$24.86 Million ≈ $17.59 Million |
-43.77pp |
| 2018-06-30 | 51.15% | AU$4.73 Million ≈ $3.34 Million |
AU$9.24 Million ≈ $6.54 Million |
+2.94pp |
| 2017-06-30 | 48.21% | AU$3.99 Million ≈ $2.83 Million |
AU$8.29 Million ≈ $5.86 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$8.83 Million ≈ $6.25 Million |
-- |
| 2006-06-30 | 16.60% | AU$1.10 Million ≈ $778.32K |
AU$6.63 Million ≈ $4.69 Million |
-26.59pp |
| 2005-06-30 | 43.19% | AU$3.48 Million ≈ $2.46 Million |
AU$8.05 Million ≈ $5.70 Million |
+22.83pp |
| 2004-06-30 | 20.37% | AU$1.00 Million ≈ $707.56K |
AU$4.91 Million ≈ $3.47 Million |
-15.40pp |
| 2003-06-30 | 35.77% | AU$2.13 Million ≈ $1.51 Million |
AU$5.96 Million ≈ $4.21 Million |
-6.81pp |
| 2002-06-30 | 42.57% | AU$2.80 Million ≈ $1.98 Million |
AU$6.58 Million ≈ $4.65 Million |
-15.35pp |
| 2001-06-30 | 57.92% | AU$4.54 Million ≈ $3.21 Million |
AU$7.83 Million ≈ $5.54 Million |
-30.91pp |
| 2000-06-30 | 88.83% | AU$4.00 Million ≈ $2.83 Million |
AU$4.50 Million ≈ $3.19 Million |
-- |
About Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more